Ayers EC, Li S, Medeiros LJ, et al. - Researchers performed this retrospective review of 195 patients from 19 academic centers in order to analyze the outcomes of platinum-based second-line immunochemotherapy in patients with non-Burkitt, aggressive B-cell lymphomas and relapsed/refractory disease following first-line treatment with intensive immunochemotherapy regimens, focusing on progression-free survival (PFS) and overall survival (OS) assessed from the time of receipt of second-line immunochemotherapy. With second-line immunochemotherapy, the estimated overall response rate was 44%, and the estimated median PFS and median OS were 3 months and 8 months, respectively. Findings revealed poor outcomes following the receipt of standard second-line immunochemotherapy in patients with early treatment failure following intensive first-line immunochemotherapy.